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j Abstract The aim of the presented study was to
compare schizophrenia and schizoaffective patients
early in the course of the disease with and without
comorbid substance abuse disorder (SUD vs. NSUD)
with regard to brain morphology. In a prospective
design 41 patients (20 SUD vs. 21 NSUD) diagnosed as
recent-onset schizophrenia or schizoaffective disorder
consecutively admitted to hospital received stan-
dardized psychopathological evaluation (BPRS, SANS,
MADRS, CGI, GAF) and MRI scanning with volu-
metric measurement of superior temporal gyrus
(STG), amygdala-hippocampal complex, and cingu-
lum. Patients with SUD (primarily cannabis) were
signiﬁcantly younger, predominantly male and had a
lower socioeconomic status. Despite less attentional
impairment (SANS subscore) and elevated anxiety/
depression (BPRS subscore) in patients with SUD
compared to NSUD, no other psychopathological
differences could be detected. There were no differ-
ences in the assessed temporolimbic brain morphol-
ogy between the two subgroups. In conclusion, in this
study substance abuse in recent-onset psychosis had
no effect on brain morphology and the earlier onset of
psychosis in patients with comorbid SUD could not
be explained by supposed accentuated brain abnor-
malities in temporolimbic regions.
j Key words substance abuse Æ cannabis Æ recent-
onset schizophrenia Æ ﬁrst-episode psychosis Æ brain
morphology Æ magnetic resonance imaging
Introduction
Brain abnormalities identiﬁed in schizophrenia using
neuropathological and neuroimaging techniques
reveal evidence for structural and functional impair-
ment in multiple brain regions focusing on frontal
cortex, temporal cortex, thalamus, hippocampal
complex, basal ganglia and even cerebellum [3]. Meta-
analyses and reviews of published studies concerning
volumetric measurements obtained by magnetic res-
onance imaging (MRI) e.g. [58, 71] have demon-
strated ventricular enlargement and volume decrease
especially of frontal and temporal lobe structures
in schizophrenia, independent of the country of
origin where the studies were conducted [14]. A meta-
analysis of volumetric structural MRI studies inves-
tigating hippocampus reported a 4% bilateral volume
reduction in schizophrenic patients [43], while some
studies observed pronounced decrease of hippocam-
pal structure only on the left side e.g., [57]. Abnor-
malities of temporal lobe structures linked to
mesolimbic system were suggested as responsible for
cognitive and emotional disturbance commonly seen
in schizophrenia. Temporal volume reductions have
been linked to clinical features [27]. Especially
reduced bilateral hippocampal size has been associ-
ated with memory deﬁcits, and the decrease of total
volume of superior temporal gyrus (STG) correlates
with the severity of thought disorder and auditory
hallucinations [4, 57]. In ﬁrst-episode and neurolep-
tika-naive patients results of volumetric MRI studies
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neuroleptika-naive patients up to 20% compared to
healthy controls was observed in most studies, but
volume changes of cerebral structures are less
conclusive. While most studies failed to detect a vol-
ume reduction in basal ganglia [32, 65], a decreased
thalamus volume was frequently reported (in the
range of 5–18% of thalamus volume compared to
controls) [20, 23, 26]. Additionally gray matter of
frontal and temporal lobe structures, especially en-
torhinal cortex and hippocampus, was found reduced
[27, 30, 63].
Substance abuse in individuals with schizophrenia
is very common and has risen to the most prevalent
comorbid psychiatric condition associated with
schizophrenia [16]. Estimated life-time prevalence
rates for substance abuse in schizophrenia range from
approximately 10 to 65% [32, 41, 52]. Besides the legal
substances tobacco and alcohol, cannabis seems to be
the most illicit drug abused in schizophrenics and has
been discussed as an important risk factor for
developing schizophrenia [5, 72]. In recent epidemi-
ological studies in European countries lifetime can-
nabis abuse in male schizophrenics under the age of
36 years was reported in up to 60% [19]. Persisting
comorbid substance use disorder (SUD) has been
associated with a negative outcome like more fre-
quent and longer periods of hospitalization, higher
relapse rates even in ﬁrst-episode patients, elevated
EPS-rates, lower medication compliance, violence and
unemployment [18, 33, 35, 41, 45, 51, 57, 60, 62].
Despite the high prevalence of comorbid SUD in
schizophrenia and the proposed impact of cannabis
abuse as an additional biological risk factor for the
onset or development of schizophrenic psychosis,
there is still few knowledge about the inﬂuence of
substance abuse on brain morphology in schizo-
phrenic patients.
Subjects and methods
In a prospective design we studied 68 inpatients with recent-onset
psychosis consecutively admitted to hospital, in the years 1996–
1999, fulﬁlling the following inclusion criteria: age between 18 and
40 years, ﬁrst hospitalisation due to schizophrenic symptoms, ill-
ness duration since the onset of ﬁrst psychotic symptoms not
preceding more than 3 years, receiving antipsychotic medication
not longer than 6 weeks prior to admission. All patients provided
informed consent before entering the study and did not present a
diagnosis of mental retardation. The study design was approved by
the local ethics committee. Diagnoses were based on clinical
interview according to ICD-10 criteria, and were consented within
all members of the study group and the treating clinical psychia-
trist, who was blind to the aims of the study. Patients were excluded
from the study if they met any of the following criteria: organic
central nervous system disorder (e.g., epilepsy, traumatic brain
injury, infectious or toxic cerebrovascular disease), mental retar-
dation, age less than 18 years or greater than 40 years, or inade-
quate knowledge of the German language. In addition to the clinical
interview, drug screens (urine) were systematically performed on
admission.
The ﬁnal study sample comprised of 41 patients diagnosed as
schizophrenia or schizoaffective disorder, who received the inter-
view, the psychopathological rating and underwent MR imaging
due to study protocol. The remaining 27 patients fulﬁlled exclusion
criteria for MR imaging of refused participation in the MRI part of
the study.
j Clinical ratings
Recorded were socioepidemiological (age at recruitment, years of
education, status of employment, family status, family history of
psychiatric diseases) and clinical data. All patients received
standardized psychopathological evaluation. For the assessment of
positive, negative and general psychopathology the 18-item ver-
sion of the brief psychiatric rating scale (BPRS) [46], and the scale
for the assessment of negative symptoms (SANS) [2] were used.
For further analyses and statistical comparisons the ﬁve subscales
anxiety/depression, anergia, thought disturbance, activation, and
hostility/suspiciousness of the BPRS and the subscales of the
SANS affective ﬂattening, alogia, avolition/apathy, anhedonia and
attentional impairment were used. Additionally, depressive
symptoms were assessed by the montgomery asberg depression
rating scale (MADRS) [40]. Global clinical evaluation was per-
formed using the clinical global impressions scale (CGI) [28] for
disease severity and the global assessment of functioning scale
(GAF), used in DSM-IV (Axis V), measuring an individual’s
functional capacity [24]. Substance use patterns and severity of
substance use was assessed by the German version of the Euro-
pean addiction severity index (EuropASI), a standardized clinical
interview demonstrating high reliability and validity in patients
with alcohol and drug dependence [53]. Premorbid intelligence
was estimated by a test of verbal knowledge and language (MWT-B)
[34].
j MRI acquisition and volumetric measurement
Magnetic resonance imaging (MRI) was performed on a 1.5 T
Scanner (Magneton Vision, Siemens) with coronal T1-weighted
MPRAGE sequences (magnetisation prepared rapid gradient echo,
repetition time = 15 ms, echo time = 5 ms, ﬂip angle = 30 ,1
aquisition, matrix 160 mm · 256 mm) generating 220 consecutive
slices of 1.0 mm thickness. Additionally T2-weighted DETSE se-
quences (double echo turbo spin echo) and T1-weighted spin echo
sequences were acquired. The images were ﬁltered for inter-slice
intensity inhomogeneities. Brain images were realigned in three
dimensions to standardize the differences in head tilt during image
acquisition. Standardized scans were then reconstructed into entire
contiguous coronal images with a 2.2-mm thickness, perpendicular
to the anterior-posterior commissure (AC-PC) line. Manual area
measurements were obtained using the Analyze 3.0 software tools.
The regions of interest (ROIs) out of the temporolimbic structures
were determined according to the literature e.g. [58]. Separate
measurements were obtained for the left and right hemisphere. The
person, who performed the manual measurement, was not involved
in the clinical rating or treatment and blind to the patients diag-
nosis.
j Amygdala-hippocampal complex
Neuroanatomical boundaries were based on operationalized crite-
ria from postmortem histological work [7] and prior published
studies e.g. [67]. The posterior boundary of the hippocampal for-
mation began where an ovoid mass of gray matter appeared infe-
riomedially to the trigone of the lateral ventricle. The fasciola
cinerea, gyrus fasciolaris, isthmus, and crus of the fornix were
excluded from measurement. Following the interruption of the
pulvinar by the crus of the fornix, all CA segments (CA1, CA2, CA3,
CA4), dentate gyrus, alveus, parasubiculum, presubiculum, and
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boundary was the coronal slice posterior to the one where the
cisterna pontis became clearly visible.
The amygdala was measured from the posterior slice in which it
ﬁrst became visible. Its anterior boundary was the slice in which the
anterior commissure appeared.
j Superior temporal gyrus (STG)/heschl’s gyrus (HG)
The anterior border of the STG was deﬁned by a vertical on the
sagittal plane, where in coronal and axial view the STG could be
clearly separated from the temporal pole. The posterior border was
determined by a vertical line where the lateral ﬁssure is capped by
the supramarginal gyrus on the sagittal plane. The superior and
inferior borders were determined by the CSF of the lateral ﬁssure
and the superior temporal sulcus, respectively. Tracing was per-
formed on the coronal plane and controlled in axial view. The gyrus
was bounded inferiorly by the superior temporal sulcus and
superiorly by the CSF of the lateral ﬁssure. The transversal gyrus
(Heschl’s Gyrus, HG) was included in the measurement, com-
mencing from a point at the posterior margin of the insula next to
the end of an opercular branch of the postcentral gyrus and ter-
minating in the lateral border of STG.
j Cingulate gyrus
As the posterior boundary of the cingulate gyrus a vertical line was
chosen touching the most posterior tip of the outer surface of the
callosal splenium. The anterior boundary was represented by a
vertical line touching the most anterior tip of the outer surface of
the callosal genu. The cingulate sulcus represented the superior
boundary and the callosal sulcus was the inferior boundary of the
cingulate gyrus. The cingulate was traced on alternating serial
coronal slices. Sagittal and transaxial slices were also examined to
obtain an overall view of the cingulate gyrus.
j Statistics
Statistical analysis were carried out using the SPSS–PC package
(Version 10.0) [44]. For the comparison of psychopathological
items and MRI volumes (ROI) parametric (two-tailed t test) and
non-parametric procedures (Mann–Whitney-U test) were used. The
alpha level was set at 0.05. In addition, an analysis of covariance
(ANCOVA) was performed to test the inﬂuence of age, body height,
gender, handedness and education on ROI volumes. For additional
analysis the general linear model procedure (GLM) was calculated
using a multivariate approach with ROI volumes as dependent
variables, diagnostic subgroups (schizophrenic patients with and
without comorbid SUD) as factors, while age and height served as
covariates. Further interaction terms were included in the model as
needed. The relations between regional volumes and subject char-
acteristics (age, symptom severity) were examined by using Pear-
son correlation coefﬁcients.
Results
According to structured clinical interview (Europ-
ASI) lifetime drug abuse was reported by 32 of 68
patients with recent-onset schizophrenia or schizoaf-
fective disorder. The abused drug (lifetime) was in 31
patients cannabis (THC), in nine patients stimulants
(amphetamines, ecstasy), in six patient cocaine, in
four patients opiates, in four patients hallucinogens,
and in four patients alcohol. In all cases the patients
experienced their ﬁrst hospitalization due to schizo-
phrenic psychopathology. In 20 patients delta-9-
tetrahydrocannabinol (THC) or metabolites, in two
patients derivates of amphetamines, and in two pa-
tients both substances could be detected in urine at
the time of admission.
The MRI study sample comprised of 41 patients
with recent-onset psychosis (36 with schizophrenia
and ﬁve with schizoaffective disorder). In this sample
lifetime drug abuse was reported by 20 patients with
recent-onset schizophrenia (THC 20 patients,
amphetamines/ecstasy seven patients, opiates two
patients, cocaine eight patients, hallucinogens one
patient, alcohol two patients). About 90% of the
patients reporting lifetime drug abuse consumed THC
in the last 6 months before imaging, of those users
33% consumed THC at least weekly. 80% of the eight
cocaine using patients and all amphetamine/ecstasy
using patients reported abuse in the last 6 months
before imaging. 16 patients with recent-onset
schizophrenia and ﬁve patients with recent-onset
schizoaffective disorder of the MRI study sample
reported no lifetime drug abuse.
To rule out a selection bias we compared the 27
patients not undergoing MR imaging with the 41
patients of the MRI study sample with regard to
sociodemographic and clinical characteristics. In the
27 patients the percentage of lifetime drug abusers
(44.4% vs. 49.0%; P = NS., v
2 test) and schizoaffective
patients (14.8% vs. 12.5%; P = NS., v
2 test) were
similar to that of the MRI study sample. In addition
there were no differences in the substance abuse
pattern (THC > cocaine > amphetamines/ecstasy),
the age (25.2 vs. 26.95 years; P = 0.461), CGI (6.56 vs.
6.45; P = 0.811), GAF (28.37 vs. 27.58; P = 0.535),
BPRS sum score (52.52 vs. 55.25; P = 0.347), SANS
composite score (39.07 vs. 42.79; P = 0.518) or
MADRS sum score (16.42 vs. 16.90; P = 0.753, all
Mann–Whitney-U test).
Sociodemographic characteristics of the MRI study
simple divided by the subgroups of schizophrenic
patients with comorbid substance use disorder (SUD)
and without substance abuse (NSUD) are presented in
Table 1. Compared with nonabusers the sample of
substance abusers was signiﬁcantly younger, pre-
dominantly male, and less married or living with a
partner. Although the difference was not signiﬁcant,
schizophrenic patients with SUD had in most cases a
lower level of education, had lower income and rate of
employment, and revealed higher rates of ﬁrst and
second degree relatives with substance use disorders
(mostly alcohol use disorder) and lower rates of
family members with severe mental illness (SMI) (e.g.
schizophrenic spectrum disorders, bipolar disorder
and major depression).
Only slight differences in psychopathology con-
cerning negative symptoms could be detected.
Attentional impairment, expressed through the SANS
subscore, was signiﬁcantly less in abusers than in
nonabusers on admission, while the SANS subscore
30Alogia and the SANS composite score were lower only
at a trend level in schizophrenic patients with SUD
compared to those without substance abuse. Schizo-
phrenic patients with comorbid SUD showed more
anxiety and depression assessed with the corre-
sponding BPRS subscale compared to those without
substance abuse. There were no other signiﬁcant
differences in positive, negative and general psycho-
pathology assessed by BPRS total score and the
remaining BPRS and SANS subscales. In addition,
depressive symptoms assessed with the MADRS in
schizophrenic patients with SUD were similar to those
of patients without substance abuse. Clinical ratings
of disease severity (CGI) and global functioning
showed similar results in both patients groups.
Table 2 presents more detailed results.
Since it has been demonstrated that chronic
administration of antipsychotic medication could
inﬂuence brain morphology (e.g. volume of caudate
nucleus, 31) the pattern and dosage of administered
psychotropic medication was compared between
abusers (SUD) and nonabusers (NSUD) in our study
sample. There was no signiﬁcant differences between
these subgroups in regard to this. Patients were
treated mostly with ﬁrst-generation antipsychotics
alone or in combination with second-generation an-
tipsychotics (SUD v. NSUD; 77% vs. 85%). Scoring for
extrapyramidal symptoms (EPS) revealed no signiﬁ-
cant differences between schizophrenic patients with
and without SUD (P = NS, Mann–Whitney-U test),
additionally there was no signiﬁcant difference in
mean chlorpromazine equivalents (P = NS, Mann–
Whitney-U test).
The measured regional volumes were normally
distributed (Kolmogorov-Smirnov-Test). Comparing
the volumes of the selected ROIs no signiﬁcant dif-
ferences could be detected between schizophrenic
patients with and without comorbid SUD (two-tailed t
test, P = NS). For additional analysis a general linear
model procedure (GLM) was calculated using a mul-
tivariate approach with ROI volumes as dependent
variables, diagnostic subgroups (schizophrenic pa-
tients with and without comorbid SUD) as factors,
while age and body height served as covariates. Again,
no signiﬁcant inﬂuence of the subgroups on regional
brain volumes could be found. Table 3 shows the ROI
volumes (raw values in cubic centimetres) of both
subgroups.
In a previous study we found in a sample of
patients with recent-onset psychosis aged 18–59 years
a decreased superior temporal gyrus asymmetry index
in the subgroup of patients without SUD compared to
those with comorbid SUD, suggesting more subtle
brain abnormalities in psychotic patients without
comorbid SUD [64]. Asymmetry index (AI) was cal-
culated as followed: AI ¼ð Volumeright   VolumeleftÞ=
0:5  ð Volumeright þVolumeleftÞ [22]. In the here
presented study there were no signiﬁcant differences
in regional asymmetry indices between the subgroups
(Mann–Whitney-U test, AHC-AI was not normally
distributed) (for details see Table 4).
To detect an inﬂuence of brain morphology on
psychopathology we performed correlations between
the BPRS total score, SANS composite score, the
related subscales and the volumes of the region of
interests (Pearson’s product-moment correlations).
No signiﬁcant association between psychopathologi-
cal items and the volumes of the measured meso-
limbic structures could be detected. In addition we
performed correlations between a semiquantitative
estimation of substance abuse (THC, cocaine,
amphetamine/ecstasy, on a scale from 0 to 4, whereas
0 means to have no problem and 4 to have severe
problems resulting from substance abuse) and volu-
metric data. We ﬁnd no signiﬁcant correlation
Table 1 Comparison of sociodemographic characteristics
SUD NSUD P
No. of patients (% of all patients) 20 (49%) 21 (51%) –
Age; in years (mean, SD)
a 23.7 ± 6.0 30.5 ± 6.9 0.002
Male gender; No. (% of group)
b 17 (85%) 10 (48%) 0.013
Unmarried (% of group)
b 95% 57% 0.005
Education less than 10 years
(% of group)
b
70% 52% 0.254
Unemployed (% of group)
b 35% 14% 0.127
Family history (in % of group)
b
Severe mental illness (SMI) 5.0% 19.1% 0.175
Substance use disorder (SUD) 20.0% 4.8% 0.070
Others 5.0% 14.3% 0.323
P probability, SD standard deviation, SUD substance use disorder, NSUD no
substance use disorder
aMann–Whitney-U test
bChi-square-test
Table 2 Comparison of clinical characteristics on admission
SUD NSUD P
No of patients (%) 20 (49%) 21 (51%) –
CGI (mean, SD) 6.4 ± 0.8 6.6 ± 0.6 0.318
Premorbid IQ (language test)
(mean, SD)
104 ± 18 102 ± 10 0.650
GAF (mean, SD) 29.3 ± 7.5 26.1 ± 6.9 0.396
BPRS total score 56.3 ± 10.7 54.1 ± 10.6 0.557
BPRS-subscales (mean, SD)
Anxiety/depression 12.9 ± 3.7 10.6 ± 4.4 0.029
Anergia 9.1 ± 3.8 10.5 ± 4.9 0.387
Thought disorder 14.6 ± 3.7 13.0 ± 5.2 0.266
Activation 9.6 ± 4.3 10.1 ± 4.8 0.773
Hostility/suspiciousness 10.2 ± 4.1 9.8 ± 3.4 0.752
SANS-composite score, (mean, SD) 36.5 ± 22.5 48.3 ± 22.8 0.065
SANS-subscales (mean, SD)
Affective flattening 6.8 ± 8.1 9.4 ± 8.7 0.261
Alogia 5.0 ± 3.7 7.6 ± 5.3 0.057
Avolition/apathy 5.2 ± 3.2 4.9 ± 3.1 0.600
Anhedonia 8.2 ± 4.9 10.8 ± 5.6 0.130
Attentional impairment 3.0 ± 2.2 4.8 ± 2.6 0.014
MADRS (mean, SD) 15.5 ± 8.4 18.8 ± 8.8 0.301
P probability, Mann–Whitney-U Test, SD standard deviation; SUD substance use
disorder, NSUD no substance use disorder, CGI clinical global impressions, GAF
global assessment of functioning, BPRS brief psychiatric rating scale, SANS scale
for the assessment of negative symptoms, MADRS montgomery asberg
depression rating scale
31between the severity of substance abuse and brain
morphology.
As patients with schizoaffective disorder were only
present in the nonabusing (NSUD) group, we com-
pared these ﬁve patients with the remaining 16
schizophrenia NSUD patients with regard to psycho-
pathology and MR volumetry. We found nearly
identical mean scores for CGI, GAF, BPRS and
MADRS in both subgroups. Patients with schizoaf-
fective disorder presented less negative symptoms
(SANS composite score), but the difference was not
statistically signiﬁcant (37.8 vs. 51.6; P = 0.354;
Mann–Whitney-U test). The schizoaffective patients
had greater ROI volumes than the schizophrenia
patients, but this was statistically signiﬁcant only for
the left superior temporal gyrus (21.1 vs. 18.7 ccm;
P = 0.042, two-tailed t test). This remained not sig-
niﬁcant after Bonferroni adjustment. If patients with
schizoaffective disorder were excluded and only the
schizophrenia patients in the NSUD (n = 16) and
SUD (n = 20) group were compared, no signiﬁcant
volumetric differences between these subgroups could
be detected.
Discussion
One of the aims of the study presented here was to
investigate if there is a difference in subtle brain
abnormalities between schizophrenia and schizoaf-
fective patients with and without comorbid SUD
even in the early course of the disorder. It could be
expected that individuals with schizophrenia who use
substances would show additional ventricular
enlargement and reduced volume of mesolimbic
structures due to literature describing poor outcome
of schizophrenic patients with comorbid substance
use disorder and in respect of the knowledge that the
extended use of substances (e.g. alcohol, cocaine) can
lead to cortical atrophy or reduction of gray matter
concentration [21, 30]. A previous study found sig-
niﬁcant volume reductions in schizophrenics with
comorbid alcoholism compared to patients without
this comorbidity [36].
However, our study could not conﬁrm the sug-
gestion of reduced regional brain volumes in schizo-
phrenic patients with comorbid substance abuse. In
our sample patients with recent-onset schizophrenia
or schizoaffective disorder with comorbid substance
abuse did not differ signiﬁcantly in terms of volu-
metric morphometry in temporolimbic regions from
schizophrenia patients without substance abuse. One
explanation for the different ﬁndings could be that the
preferred drug in our sample was cannabis and
alcohol consumption was not extensive enough in the
SUD patients to cause cortical atrophy or ventricular
enlargement. The effect of cannabis consumption on
brain volume is less clear as that of alcohol. The
structural neuroimaging studies in cannabis abusers
revealed conﬂicting results [48]. While two studies
could not demonstrate an inﬂuence of cannabis on
brain morphology, especially on hippocampus, com-
pared to controls [6, 66], a third study found lower
gray matter volumes in the right parahippocampal
region, lower white matter density in the left parietal
region as well as increased volumes of bilateral fusi-
form gyrus, right thalamus and left parahippocampal
region in the group of chronic cannabis users [37].
Table 3 Comparison of regional
brain volumes (ROI) SUD NSUD P
No of patients (%) 20 (49%) 21 (51%) –
Left AHC (mean, SD), ccm 3.27 ± 0.58 3.02 ± 0.40 0.134
Right AHC (mean, SD), ccm 3.28 ± 0.61 3.13 ± 0.46 0.380
Left STG/HG (mean, SD), ccm 17.72 ± 2.32 19.30 ± 2.60 0.121
Right STG/HG (mean, SD), ccm 19.52 ± 2.28 20.17 ± 2.47 0.820
Left cingulate gyrus (mean, SD), ccm 9.03 ± 1.72 8.86 ± 1.74 0.925
Right cingulate gyrus (mean, SD), ccm 8.61 ± 1.47 8.76 ± 1.70 0.799
P probability, two-tailed t test, SD standard deviation, ccm cubic centimetre, SUD substance use disorder, NSUD no
substance use disorder, ROI region of interest, AHC amygdala-hippocampal complex, STG/HG superior temporal gyrus/
heschl’s gyrus
Table 4 Comparison of regional
asymmetry indices (ROI) SUD NSUD P
No of patients (%) 20 (49%) 21 (51%) –
AI—AHC (mean, SD) )0.035 ± 0.199 )0.0002 ± 0.177 0.130
AI–STG/HG (mean, SD) +0.098 ± 0.081 +0.045 ± 0.126 0.157
AI—cingulate gyrus (mean, SD) )0.043 ± 0.190 )0.011 ± 0.167 0.620
Asymmetry Index was calculated as followed:AI ¼ð Volumeright  VolumeleftÞ=0:5  ð Volumeright þ VolumeleftÞ
P probability, Mann–Whitney-U test, SD standard deviation, SUD substance use disorder, NSUD no substance use disorder,
AI asymmetry index, ROI region of interest, AHC amygdala-hippocampal complex, STG/HG superior temporal gyrus/heschl’s
gyrus
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matter volume percentage in the group of substance
abusers (cannabis, opiates, cocaine) compared to
healthy controls [54]. Another study without healthy
control group revealed a signiﬁcant correlation
between age of ﬁrst use and decreased total brain
volume [68]. Subjects who started using marijuana
before age 17, compared to those who started later,
revealed smaller whole brain and percent cortical
gray matter and larger percent white matter volumes
[68].
A previous study examining brain volumes in
cannabis-exposed patients with schizophrenia versus
non-exposed patients with schizophrenia revealed no
differences between the subgroups for total brain
volume, total gray and white matter, ventricles, cere-
bellum and caudate except a decreased asymmetry of
the lateral ventricles in the cannabis-exposed patients
[10]. In a recent longitudinal study the same research
group could demonstrate that ﬁrst-episode schizo-
phrenia patients with continued use of cannabis
showed increased loss of cerebral gray matter volume
and larger increases of in lateral and third ventricle
volumes than healthy subjects and patients who did
not use cannabis during the follow-up [50]. The
amount of cannabis used were not speciﬁed in the
publication while it was assessed based on patients
and relatives estimation. No information on a dose–
response relationship was provided. Nevertheless,
brain volumes of schizophrenia patients with and
without cannabis abuse did not differ signiﬁcantly at
the beginning of the longitudinal study, although it
has to be assumed that the patients abused cannabis
several years before entering the study and the mean
duration of schizophrenic illness is more than one
year. This cross-sectional ﬁnding is in line with our
results. However, a further study investigating the
volumes of the superior frontal gyrus, anterior cin-
gulated gyrus and orbital frontal lobe found less
anterior cingulate gray matter in cannabis abusing
ﬁrst-episode schizophrenia patients compared with
patients who did not abuse cannabis and healthy
volunteers [64]. The association of reduced volume in
anterior cingulate gyrus and the history of cannabis
abuse in schizophrenia was more interpreted in the
context of a disturbed function of the anterior cin-
gulate with the consequence of poor decision-making
and more compulsive drive towards drug use as a
predisposition for substance abuse than as a toxic
effect of cannabis itself. This contrasts with our
results of no volumetric differences in the anterior
cingulate between the two groups of schizophrenia
patients. Although no data regarding the amount of
cannabis consumption was given in both studies, one
could speculate if differences in substance use are
responsible for the conﬂicting results. Interestingly,
neither the cross sectional study [64] nor the longi-
tudinal study at the beginning [50] showed volumet-
ric differences between ﬁrst-episode schizophrenia
patients and healthy controls except larger third
ventricle in the schizophrenia group [50].
To our knowledge our study is the ﬁrst comparing
different temporolimbic brain volumes with the
region of interest (ROI) method (anterior cingulate,
STG, amygdala/hippocampus) in schizophrenia
patients exposed to illegal drugs versus schizophrenia
patients without a history of illegal drug abuse. The
measured volumes of the selected ROIs (amygdala-
hippocampal complex, superior temporal gyrus,
cingulum) are in the range of the presented data in
literature [38, 39, 43], taking into account that our
measurement of STG includes the transversal gyrus,
and the extraction of the cingulum was not restricted
to the anterior part. Nevertheless the heterogeneity of
the deﬁnition of the regional volume (ROIs) bound-
aries, differences in MRI techniques and volume
extractions in previous studies make it difﬁcult to
compare our volumetric measurements. Decreases
of gray and white matter volume over time may be
related to the duration, type and cumulative dose
of antipsychotic medication patients received [9].
Because the percentage of patients treated with second
generation antipsychotics and the dose of conven-
tional antipsychotics (chlorpromazine-equivalents)
was similar in both subgroups, medication served not
as biasing factor in our volumetric study. Long-term
effects of antipsychotic medication or chronicity of
illness are not to expect in a sample of patients with
recent-onset schizophrenia.
The described sociodemographic characteristics in
both patient subgroups are consistent with literature,
revealing younger age, less education, less married
and higher rates of unemployment in the substance
abuser group [16, 17, 35, 41, 59]. The frequency
of substance abuse in recent-onset schizophrenia
observed in our study sample is also in line with the
reported prevalence rates in ﬁrst-episode schizo-
phrenic spectrum disorder [1, 12, 35, 49]. The pattern
of abused drugs is similar to that observed in Euro-
pean studies, presenting high prevalence of cannabis
and low prevalence of cocaine abuse in contrast to US
surveys showing high rates of cocaine consumers [25,
42, 56, 57]. Differences in psychopathology between
abusers and nonabusers were reported inconsistently
in the recent literature. Comorbid substance abuse
has been associated with higher positive symptom-
atology [8, 13, 45, 61], lower negative symptoms [5,
47, 61], and fewer positive and negative symptoms
[17]. Because the overall differences in psychopa-
thology between substance using and nonusing
schizophrenics were small [61], our results of similar
scores in positive, negative and general symptoms are
in line with literature.
Substance abuse may contribute to an earlier
onset of schizophrenia as seen in our sample
and as demonstrated in some [12, 41, 49], but not
in the majority of previous studies [11, 17, 47,
62]. Substance abuse in ﬁrst-episode schizophrenia
33(preferentially cannabis) may not lead to more brain
abnormalities detectable by volumetric morphometry,
which were frequently reported in schizophrenia. The
results of the presented MRI study with no difference
in brain morphology between substance abusing and
nonabusing schizophrenia patient is in line with our
previous ﬁndings of similar neurocognitive perfor-
mance of these subgroups [70]. Preliminary analysis
of own MRI data including ﬁrst-episode patients with
an age above 40 demonstrated even fewer subtle
abnormalities of brain morphology in schizophrenia
patients with comorbid substance abuse [69],
suggesting that in this subgroup neurotransmitter
changes or functional abnormalities due to substance
abuse serve as a main risk factor for the onset of
schizophrenia. Nevertheless, the now presented
results support the hypothesis that the earlier psychosis
onset of schizophrenia patients using illegal drugs does
not depend on pronounced brain abnormalities.
There are several limitations of our study. The
sample size may be too small to detect signiﬁcant
differences in volumetric measures. We did not match
the group of abusers with nonabusers for age, gender
or education and had no comparison with a healthy
control group. The missing control group did not
allow us to prove if the patients in our sample display
volumetric reductions of brain volume at all com-
pared to healthy subjects. Although we collected data
about the pattern of substance abuse, we did not
evaluate exactly the frequency and amount of sub-
stances consumed by the patients. In consequence we
could not investigate the relationship of the quantity
of abused drugs and changes in brain morphology in
the way of a ‘‘dose–response’’ relationship.
Only the nonabusing group contained schizoaf-
fective patients. This could have potentially biased
our results. To minimize the bias we analysed the
schizoaffective patients in the nonabusing group
separately and found (nonsigniﬁcant) greater regional
volumes in these patients. The inclusion of these
patients leads to higher mean ROI volumes in the
nonabusing group and would have made the initially
hypothesized pronounced volumetric reduction in the
abusing group even more detectable, if there would be
such a difference between the groups.
We controlled the regional volumes for height (as
covariates) in regard to the sufﬁcient correlation of
this parameter with the intracranial volume, but we
did not measure the intracranial volume at all.
Therefore we could not compare the relative volumes,
which limits our study results. Unfortunately we
calculated no inter-rater correlation, which is also a
severe methodological limitation.
The intention of the study was comparative volu-
metric analysis of temporolimbic brain regions in a
consecutive sample of patients with recent-onset
schizophrenia eligible for inpatient treatment. There-
fore our results should be interpreted as ﬁndings in a
naturalistic and not experimental sample. Naturalistic
designs may have more clinical implications than
investigations of a strongly selected sample of patients.
Nevertheless the presented results should be inter-
preted with caution, have to be replicated and need
furtherinvestigationonlarger samplesincludingother
neurobiological parameters (e.g. genetics, functional
MRI, event related potentials) and longer follow-up
periods to evaluate a potential neurodegenerative
process in the course of schizophrenic disorder within
the presented subgroups (SUD vs. NSUD).
In conclusion, early in the course of schizophrenia
substance abuse (primarily cannabis) seems not to
lead to more brain abnormalities and the earlier onset
of psychosis in patients with comorbid substance
use compared to patients without substance abuse
could not be explained by the initially supposed
reduced brain volumes in temporolimbic regions
reﬂecting potentially higher disturbances in neuro-
development.
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